[1] SHIN YW, LEE ST, SHIN JW, et al. VGKC-complex/LGI1-antibody encephalitis:Clinical manifestations and response to immunotherapy[J]. J Neuroimmunol, 2013, 265(1-2):75-81.
|
[2] BASTIAANSEN AEM, van SONDEREN A, TITULAER MJ. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1or anti-contactin-associated protein-like 2 antibodies(formerly cal ed voltage-gated potassium channel-complex antibodies)[J]. Curr Opin Neurol, 2017, 30(3):302-309.
|
[3] GUAN HZ, REN HT, CUI LY. Autoimmune encephalitis:An expanding frontier of neuroimmunology[J]. Chin Med J(Engl), 2016, 129(9):1122-1127.
|
[4] XIA ZY, HAN T, MENG HJ. Early immunosuppression combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis[J]. Clin J Med Offic, 2020, 48(1):97-98,101.(in Chinese)夏志勇,韩涛,孟红军.早期免疫抑制联合熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效[J].临床军医杂志,2020, 48(1):97-98, 101.
|
[5] LAN RY, CHENG C, LIAN ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis[J]. Hepatology, 2006, 43(4):729-737.
|
[6] GAO XS, ZHANG YN, LIU T, et al. Osteoporosis in patients with primary biliary cirrhosis[J/CD]. Chin J Liver Dis(Electronic Edition), 2018, 10(3):56-60.(in Chinese)高学松,张耀南,刘婷,等.原发性胆汁性肝硬化患者合并骨质疏松症临床研究[J/CD].中国肝脏病杂志(电子版),2018, 10(3):56-60.
|
[7] AGMON-LEVIN N, KOPILOV R, SELMI C, et al. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease[J]. Immunol Res, 2015, 61(1-2):141-146.
|
[8] WEISSERT R. Adaptive immunity is the key to the understanding of autoimmune and paraneoplastic inflammatory central nervous system disorders[J]. Front Immunol, 2017, 23(8):336.
|
[9] DANNER OK, MATTHEWS LR, FRANCIS S, et al. Vitamin D3suppresses class II invariant chain peptide expression on activated-B-lymphocytes:A plausible mechanisms for downregulation on acute inflammatory conditions[J]. J Nutr Metab,2016, 2016:4280876.
|